Skip to main content

Year: 2023

Press release Biocartis NV: Biocartis Hosts Corporate Workshop and Announces Seven Idylla™ Abstracts to be Presented at AMP 2023 Annual Meeting

PRESS RELEASE – 13 November 2023, 07:00 CET Biocartis Hosts Corporate Workshop and Announces Seven Idylla™ Abstracts to be Presented at AMP 2023 Annual Meeting Mechelen, Belgium and Itasca (IL), United States, 13 November 2023 – Biocartis, an innovative molecular diagnostics company, announces today that it will host a free corporate workshop at the Annual Meeting of the ‘Association for Molecular Pathology’ (AMP), a leading molecular diagnostics conference, taking place between 14-18 November 2023 in Salt Lake City, Utah (US). In addition, seven abstracts that used the Idylla™ Platform and were performed by a variety of US laboratories and research institutes will be presented at this conference. The workshop (15 November 2023, 14:00-14:50 MST) will focus on how patient management in personalized medicine can be expedited...

Continue reading

IMCD India to acquire two business lines from CJ Shah & Company

main visual_IMCD India to acquire two business lines from CJ Shah & CompanyPhotographed from left to right: •Mr. Aashil Shah, Head of Strategy, CJ Shah & Company•Mr. Shaurya Shah, Head of Business Development, CJ Shah & Company•Mrs. Shital Shah, Partner, CJ Shah & Company•Mr. Apurva Shah, Managing Partner, CJ Shah & Company•Mr. Narendra Varde, Managing Director, IMCD India & Bangladesh•Mr. Frank Schneider, Business Group Director, IMCD Coatings & Construction•Mr. Saurin Shah, Regional Director – Indian Sub-Continent & Middle East, Coatings & Construction•Mr. Ramanuj Kankani, Director – Finance & Operations, IMCD India & Bangladesh•Mr. Jignesh Mehta, Director – Coatings & Construction, IMCD IndiaROTTERDAM, The Netherlands (13 November 2023) – “IMCD N.V....

Continue reading

Coop Pank AS results for October 2023

Coop Pank’s financial results in October 2023:In October, number of the bank’s clients increased by 2,500 and number of active clients increased by 2,000. By the end of the month number of clients reached 177,700 and number of active clients reached 79,400. Over the year, customer base has grown by 25%. Volume of the bank’s customer deposits increased by 57 million euros, reaching 1.76 billion euros by the end of month. Deposits of corporate customers increased by 44 million euros and deposits of private customers increased by 3 million euros. The volume of deposits attracted from international platforms increased by 10 million euros. Over the year, volume of bank deposits has grown by 27%. The bank’s loan portfolio increased by 15 million euros over the month and reached 1.50 billion euros by the end of October....

Continue reading

WISe.ART the Digital Art Platform of WISeKey, Unveils the Renaissance Coin: Revolutionizing Art Investment and Preservation with a Unique Blend of Technology and Heritage

  WISe.ART the Digital Art Platform of WISeKey, Unveils the Renaissance Coin: Revolutionizing Art Investment and Preservation with a Unique Blend of Technology and Heritage Cooperation between WISe.ART Pedro Sandoval and Global Market of Artification (GMA)GENEVA/Madrid/Rome – November 13, 2023 – WISeKey International Holding Ltd. (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leader in cybersecurity, digital identity, and Internet of Things (IoT) solutions operating as a holding company, today announced its WISe.ART subsidiary is unveiling the Renaissance Coin: Revolutionizing Art Investment and Preservation with a Unique Blend of Technology and Heritage.WISe.ART, a leading innovator in the digital art and luxury collectibles market, is set to launch the Renaissance Coin in January 2024, a groundbreaking initiative that marks a new...

Continue reading

Valneva Reports Positive Pivotal Phase 3 Immunogenicity Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate

Saint-Herblain (France), November 13, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive pivotal Phase 3 immunogenicity data in adolescents for its single-dose chikungunya virus (CHIKV) vaccine candidate VLA1553. These results complement the initial Phase 3 safety data the Company reported for the trial in August 20231. Funded by the Coalition for Epidemic Preparedness Innovations (CEPI), with support from the European Union’s Horizon 2020 program, and conducted in collaboration with Instituto Butantan, the VLA1553-321 adolescent trial is intended to support label extension in this age group following recent regulatory approval in adults from the Food and Drug Administration (FDA) in the United States (U.S)2. The trial is also expected to support licensure of the vaccine in Brazil,...

Continue reading

ZeroFox to Exhibit at Black Hat Middle East & Africa

Visit ZeroFox at Stand #H4.F18 for more information about the company’s external cybersecurity and brand protection services WASHINGTON, Nov. 13, 2023 (GLOBE NEWSWIRE) — ZeroFox (Nasdaq: ZFOX), a leading provider of external cybersecurity, will exhibit at Black Hat Middle East & Africa (MEA), which runs from November 14-16, 2023 at the Riyadh Front Exhibition & Conference Center (RFECC) in the Kingdom of Saudi Arabia. Launched in 2022, Black Hat MEA is the largest cybersecurity event in the region, expected to attract over 40,000 infosec professionals and 300 exhibitors and speakers. Conference attendees can meet with ZeroFox representatives to discuss the company’s recent product innovations in external cybersecurity and brand protection at Stand #H4.F18. More and more often, threat actors are hijacking already-established...

Continue reading

Bombardier Defense Delivers Seventh Global Aircraft for Saab’s GlobalEye Airborne Surveillance Solution

Bombardier Global aircraft misionnized into Saab GlobalEye platformBombardier Defense Delivers Seventh Global Aircraft for Saab’s GlobalEye Airborne Surveillance SolutionBombardier’s Global aircraft brings its formidable performance into Saab’s GlobalEye airborne surveillance platforms, a solution equipped with sensors for all air, sea and land domains Modern business jets are being increasingly recognized as strategic assets for military forces across the worldMONTRÉAL, Nov. 12, 2023 (GLOBE NEWSWIRE) — Bombardier Defense is proud to announce the seventh Global aircraft delivery to defense and security company Saab, ready to be transformed into Saab’s Airborne Early Warning and Control (AEW&C) solution known as GlobalEye. This new delivery comes as the two companies attend the Dubai Air Show 2023, where Bombardier...

Continue reading

Veea, Inc. and Plum Acquisition Corp. I Announce Letter of Intent for a Business Combination

NEW YORK, NY and SAN FRANCISCO, CA, Nov. 12, 2023 (GLOBE NEWSWIRE) —  Veea, Inc. (“Veea”), a leading digital transformation company, and Plum Acquisition Corp. I (“Plum”) (NASDAQ: PLMI), a special purpose acquisition company formed by Ursula Burns, Kanishka Roy, and Mike Dinsdale, today announced the signing of a non-binding letter of intent for a potential business combination. Founded in 2014, Veea offers edge-to-cloud computing with its VeeaHub® smart computing hub products, multi-user devices that can replace or complement Wi-Fi Access Points (APs), IoT gateways, routers, basic firewalls, network attached storage, and other types of hubs and appliances at user premises. Under the terms of the non-binding letter of intent, Veea and Plum would become a combined entity, with Veea’s existing shareholders exchanging their shares...

Continue reading

Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia

LDL-C Reductions Up to 55% and Blood PCSK9 Protein Reductions Up to 84% Observed After a Single Infusion of VERVE-101 at Potentially Therapeutic Doses Safety Profile Supports Continued Development of VERVE-101 Enrollment Ongoing in the 0.45 mg/kg and 0.6 mg/kg Cohorts with Plans to Initiate Expansion Cohort in 2024 Company to Host Conference Call and Webcast Today at 6:30 p.m. ET BOSTON, Nov. 12, 2023 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced first human proof-of-concept data for in vivo base editing from the ongoing heart-1 phase 1b clinical trial of VERVE-101. Treatment with VERVE-101 led to dose-dependent reductions of disease-causing low-density lipoprotein cholesterol...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.